Phase 4 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given voluntary written consent (or whose legal representative has given consent) before any screening takes place
- People who are older than 16 years of age
- People who have started intensive treatment within the past three days for one of the following blood cancer conditions: newly diagnosed acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS); OR a relapse of one of these conditions after being in remission for at least 6 months; OR preparation treatment (conditioning) before a stem cell transplant using a donor's cells; OR preparation treatment (conditioning) before a stem cell transplant using the patient's own cells
- People whose immune cells (specifically a type called neutrophils) are expected to be at very low levels for at least 7 days
- People who are expected to stay in hospital for at least 10 days
Who may not be able to join:
- People who already have a confirmed or suspected infection at the time of enrolment
- People who are already receiving broad-spectrum antibiotics (strong antibiotics that treat a wide range of infections)
- People who are critically ill and require treatment in an Intensive Care Unit (ICU)
- People with a SOFA score of 11 or higher — this is a medical severity score used by doctors to measure organ function (confirm with trial site)
- People who have already had very low immune cell levels for more than 21 days before joining the trial
- People who have previously been enrolled in this same study
- People who are unable to provide written informed consent
- People who have any other condition that, in the treating doctor's opinion, could affect their safety or ability to follow the study requirements
- People who are receiving or have previously received other treatments that, in the treating doctor's opinion, could affect their safety or the reliability of the trial results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Johan Maertens, MD, PhD, Universitaire Ziekenhuizen KU Leuven
Phone: +32 16 34 48 77
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Absence of a serious medical complication (SMC) following 42 days after randomisation. SMC is defined as: Death; and/or ICU admission; and/or Septic shock requiring vasopressive therapy.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.